Al­ways chas­ing the newest sci­ence, Schond Green­way joins MindMed; Mi­rati fills key va­can­cy with ex-Are­na fi­nance chief

From cell ther­a­py to pre­ci­sion med­i­cine, Schond Green­way has hopped from one bur­geon­ing re­search area to the next through­out his ca­reer. Now he’s head­ing off to an­oth­er: psy­che­del­ic ther­a­py.

MindMed tapped Green­way as CFO on Mon­day, as CEO Robert Bar­row guides the com­pa­ny through what he called “an ex­cit­ing point in our growth.” The New York-based psy­che­delics com­pa­ny was the sec­ond to ever go pub­lic on an Amer­i­can ex­change, be­hind Com­pass Path­ways. And this year, Bar­row’s lin­ing up “nu­mer­ous near-term mile­stones ahead across our pipeline.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.